Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis

• Published in: Advances in therapy Vol. 38; no. 6; pp. 3154 - 3165
• Main Authors: Pozo-Rosich, Patricia, Samaan, Karen H., Schwedt, Todd J., Nicholson, Robert A., Rettiganti, Mallikarjuna, Pearlman, Eric M.
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.06.2021
• Subjects: Cardiology; Endocrinology; Internal Medicine; Medicine; Medicine & Public Health; NCT; NCT02614183; NCT02614196; NCT02614261; Oncology; Original Research; Pharmacology/Toxicology; Rheumatology; Efficacy; Chronic; Galcanezumab; Episodic; Migraine; Wear off
• DOI: 10.1007/s12325-021-01708-8
• ISSN: 0741-238X; 1865-8652

Introduction The consistency of the treatment effect of galcanezumab throughout the dosing interval is examined in patients with episodic and chronic migraine. Methods This study was a post hoc analysis of clinical trial data from episodic (EVOLVE-1; EVOLVE-2; both 6-month duration) and chronic (REGAIN; 3-month duration) migraine double-blind trials evaluating the efficacy of a once-monthly injection of galcanezumab 120 mg relative to placebo. Adults with episodic (placebo, n  = 894; galcanezumab, n  = 444) or chronic migraine (placebo, n  = 558; galcanezumab, n  = 278) were included. Mean change from baseline in weekly migraine headache days, averaged across all months for each week of the dosing interval, was compared between groups and within the galcanezumab group during weeks 1 and 4. Additional analyses examined the mean difference from placebo in weekly migraine headache days and a day-by-day analysis. Results Weekly migraine headache day reduction was significantly greater with galcanezumab relative to placebo every week ( P  < 0.001) and did not differ during weeks 1 and 4 for those with episodic ( P  = 0.740) or chronic migraine ( P  = 0.231) taking galcanezumab. Estimated probabilities of migraine on day 2 and day 30 did not differ for those with episodic ( P  = 0.61) or chronic migraine ( P  = 0.616) taking galcanezumab. Conclusion This analysis demonstrates once monthly galcanezumab exhibits consistent efficacy throughout the dosing interval among the population of patients with migraine in three clinical trials evaluating the efficacy of galcanezumab. There is no evidence from these trials that the effect of galcanezumab “wears off” at the end of the dosing interval. Trial Registration ClinicalTrials.gov identifier: EVOLVE-1 (NCT02614183); EVOLVE-2 (NCT02614196); REGAIN (NCT02614261).